Silence Therapeutics (SLN) Cash & Equivalents: 2019-2025
Historic Cash & Equivalents for Silence Therapeutics (SLN) over the last 6 years, with Sep 2025 value amounting to $102.2 million.
- Silence Therapeutics' Cash & Equivalents rose 26.96% to $102.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $102.2 million, marking a year-over-year increase of 26.96%. This contributed to the annual value of $121.3 million for FY2024, which is 76.38% up from last year.
- According to the latest figures from Q3 2025, Silence Therapeutics' Cash & Equivalents is $102.2 million, which was down 10.51% from $114.2 million recorded in Q2 2025.
- Silence Therapeutics' 5-year Cash & Equivalents high stood at $143.4 million for Q1 2024, and its period low was $37.8 million during Q3 2021.
- Moreover, its 3-year median value for Cash & Equivalents was $102.2 million (2025), whereas its average is $100.9 million.
- As far as peak fluctuations go, Silence Therapeutics' Cash & Equivalents spiked by 199.34% in 2021, and later slumped by 35.14% in 2022.
- Over the past 5 years, Silence Therapeutics' Cash & Equivalents (Quarterly) stood at $99.1 million in 2021, then tumbled by 35.14% to $64.3 million in 2022, then grew by 6.99% to $68.8 million in 2023, then surged by 76.38% to $121.3 million in 2024, then climbed by 26.96% to $102.2 million in 2025.
- Its last three reported values are $102.2 million in Q3 2025, $114.2 million for Q2 2025, and $136.5 million during Q1 2025.